[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Bilici A, Ustaalioglu BB, Seker M, Kayahan S: Case report: soft tissue metastasis from immature teratoma of the testis: second case report and review of the literature. Clin Orthop Relat Res; 2010 Sep;468(9):2541-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: soft tissue metastasis from immature teratoma of the testis: second case report and review of the literature.
  • BACKGROUND: Testicular cancer, like other histopathologic types, commonly metastasizes to the lungs, liver, and brain.
  • Spread to soft tissue, however, is rare with only four cases with seminoma reported.
  • However, one case with metastasis of testicular immature teratoma to soft tissue was documented previously.
  • CASE DESCRIPTION: We report the case of a 38-year-old man with recurrent immature teratoma of the testis who presented with a painless soft tissue mass in the left thigh previously treated with standard chemotherapy.
  • After removal of the soft tissue mass, his serum alpha-fetoprotein level had returned to the normal range.
  • LITERATURE REVIEW: To our knowledge, this is the second case of immature teratoma of the testis metastasized to soft tissue.
  • PURPOSES AND CLINICAL RELEVANCE: We suggest that for a man with testicular cancer who has a soft tissue mass, metastasis of soft tissue from testicular cancer and other solid malignancies should be considered in the differential diagnosis of a soft tissue mass together with primary soft tissue sarcoma.
  • [MeSH-major] Soft Tissue Neoplasms / secondary. Teratoma / secondary. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Brain Neoplasms / therapy. Chorionic Gonadotropin, beta Subunit, Human / blood. Cranial Irradiation. Humans. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Magnetic Resonance Imaging. Male. Orchiectomy. Thigh. Treatment Outcome. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Skeletal Radiol. 2000 May;29(5):270-4 [10883446.001]
  • [Cites] Br J Radiol. 2008 Jul;81(967):e188-90 [18559897.001]
  • [Cites] AJR Am J Roentgenol. 2002 Dec;179(6):1644; author reply 1644 [12438072.001]
  • [Cites] Jpn J Clin Oncol. 2004 Apr;34(4):210-4 [15121758.001]
  • [Cites] Br J Surg. 1970 Jul;57(7):529-30 [5427475.001]
  • [Cites] Urology. 1985 Apr;25(4):398-400 [2984822.001]
  • [Cites] AJR Am J Roentgenol. 1985 Dec;145(6):1165-71 [2998169.001]
  • [Cites] Dis Colon Rectum. 1987 Oct;30(10):805-8 [2820673.001]
  • [Cites] Ann Plast Surg. 1993 Oct;31(4):377-8 [8239441.001]
  • [Cites] Clin Orthop Relat Res. 1998 Oct;(355):272-81 [9917613.001]
  • [Cites] Acta Neurol Belg. 2005 Sep;105(3):178-9 [16255156.001]
  • [Cites] Eur Urol. 2005 Dec;48(6):885-94 [16126333.001]
  • [Cites] Singapore Med J. 2007 Mar;48(3):e77-80 [17342276.001]
  • [Cites] Eur J Surg Oncol. 2007 May;33(4):508-11 [17081724.001]
  • [Cites] Cancer. 2008 Jan 1;112(1):193-203 [18040999.001]
  • [Cites] JAMA. 2008 Feb 13;299(6):672-84 [18270356.001]
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):526-34 [10947022.001]
  • (PMID = 19937408.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AFP protein, human; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins
  • [Number-of-references] 17
  • [Other-IDs] NLM/ PMC2919860
  •  go-up   go-down


2. Kasai T, Moriyama K, Tsuji M, Uema K, Sakurai N, Fujii Y: Adenocarcinoma arising from a mature cystic teratoma of the testis. Int J Urol; 2003 Sep;10(9):505-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma arising from a mature cystic teratoma of the testis.
  • Histopathological examination revealed a well-differentiated, mucinous adenocarcinoma originating from the gastrointestinal epithelium in a mature cystic teratoma (dermoid cyst) of the testis and metastatic mucinous adenocarcinoma of the skin.
  • We made a diagnosis of teratoma with malignant transformation (TMT) of the testis.
  • Combination chemotherapy with low-dose cisplatin/5'-deoxy-5-fluorouridine (CDDP/5'-DFUR) was initiated, but the patient died 8 months after orchiectomy.
  • At autopsy, similar mucinous adenocarcinoma of the testis and the skin were observed at the metastatic sites.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / secondary. Dermoid Cyst / diagnosis. Skin Neoplasms / secondary. Teratoma / diagnosis. Testicular Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12941133.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


3. Spiess PE, Pisters LL, Liu P, Pettaway CA, Kamat AM, Gomez JA, Tannir NM: Malignant transformation of testicular teratoma: a chemoresistant phenotype. Urol Oncol; 2008 Nov-Dec;26(6):595-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of testicular teratoma: a chemoresistant phenotype.
  • PURPOSE: To review our experience in the management of malignant transformation of teratoma (MTT).
  • RESULTS: Two patients presented with clinical stage I disease in which malignant transformation occurred within the primary testis tumor (rhabdomyosarcoma in 1 and adenocarcinoma in 1).
  • Of the remaining 7 patients, the clinical stages were IIA (N = 1), IIB (N = 3), and III (N = 3), and all were treated with chemotherapy followed by RPLND.
  • Following preoperative chemotherapy, a significant radiologic response (defined as more than a 25% reduction in maximum tumor circumferential diameter) was demonstrated in 1 patient, and normalization of serum tumor markers was demonstrated in 6.
  • CONCLUSIONS: In our experience, MTT is significantly resistant to current chemotherapeutic regimens, as demonstrated by its poor radiologic response to treatment.
  • Alternative therapeutic strategies targeted to MTT are thus needed.
  • [MeSH-major] Teratoma / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Drug Resistance, Neoplasm. Humans. Lymph Node Excision. Male. Neoplasm Staging. Retroperitoneal Space

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2781-8 [15837993.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 1998 Jun;89(6):622-6 [9666691.001]
  • [Cites] Semin Urol Oncol. 1998 May;16(2):65-71 [9649229.001]
  • [Cites] J Urol. 1998 Mar;159(3):859-63 [9474169.001]
  • [Cites] Scand J Urol Nephrol. 2003;37(2):177-8 [12745729.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):860-3 [2990657.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4285-91 [14645417.001]
  • [Cites] J Urol. 1998 Jan;159(1):133-8 [9400455.001]
  • [CommentIn] Urol Oncol. 2009 Mar-Apr;27(2):218; author reply 218-9 [19285238.001]
  • (PMID = 18367105.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS610854; NLM/ PMC4121060
  •  go-up   go-down


Advertisement
4. Ondrus D, Hornák M, Breza J, Mat'oska J, Schnorrer M, Belan V, Kausitz J: Delayed orchiectomy after chemotherapy in patients with advanced testicular cancer. Int Urol Nephrol; 2001;32(4):665-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delayed orchiectomy after chemotherapy in patients with advanced testicular cancer.
  • INTRODUCTION: The therapeutic procedures in the management of testicular cancer are determined by histological findings in the removed testis and by the extent of the disease at the time of diagnosis.
  • However, all advanced tumors could be treated by primary chemotherapy regardless of the histological findings.
  • The current imaging techniques (ultrasound of the testis, abdominal and chest CT examination) and laboratory tests (determination of serum tumor markers AFP and hCG) provide sufficient evidence for the presence of cancer.
  • When the diagnosis of advanced tumor is evident, it is possible to start the treatment without orchiectomy.
  • The aim of this study was to evaluate the advantages of neo-adjuvant chemotherapy with delayed orchiectomy in the management of advanced testicular cancer.
  • MATERIAL AND METHODS: A total of 36 patients with advanced germ cell testicular cancer underwent primary PVB or BEP chemotherapy without previous orchiectomy.
  • Searching for the origin, testicular tumor was detected.
  • The patients were treated with cisplatin-containing combination chemotherapy.
  • Following completion of chemotherapy, orchiectomy was performed alone or simultaneously with retroperitoneal lymph node dissection (RPLND) and/or lung metastasectomy in cases with persistent residual mass.
  • Following orchiectomy the patients were regularly checked and in cases with viable malignant tumor found in the testis sequential chemotherapy was administered.
  • Similarly when the relapse of the disease was detected, the patients were treated with sequential chemotherapy.
  • RESULTS: Complete disappearance of metastases was observed in 12 patients following chemotherapy alone.
  • The viable tumor in the removed tissue was found in one patient.
  • Delayed orchiectomy was performed simultaneously with surgical removal of residual mass in the retroperitoneum in 24 patients and as a separate procedure in 12 patients who have been considered to be complete responders following chemotherapy alone.
  • Residual viable tumor in testicular specimen was found in three patients, necrotic or fibrotic tissue in 18, and mature teratoma in 15 patients.
  • Overall survival of the patients was 26/36 (72.7%) at mean of 56.9 months (range 7-145 months, median 50 months) since the start of the treatment.
  • CONCLUSIONS: In patients with advanced germ cell testicular cancer preference must be given to the early beginning of intensive chemotherapy without the need of tissue diagnosis of primary tumor that should be obtained by orchiectomy.
  • Benefit of this therapeutic approach is the timely management of acute abdominal and/or pulmonary symptoms of life-threatening distant metastases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Cisplatin / therapeutic use. Germinoma / drug therapy. Orchiectomy. Testicular Neoplasms / drug therapy. Vinblastine / therapeutic use
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm, Residual. Survival Rate. Teratoma / secondary. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1984 Sep;2(9):1025-7 [6088708.001]
  • [Cites] J Urol. 1983 Mar;129(3):522-3 [6834536.001]
  • [Cites] J Urol. 1996 Mar;155(3):952-4 [8583615.001]
  • [Cites] Br J Cancer. 1983 May;47(5):613-9 [6189504.001]
  • [Cites] Cancer. 1995 Feb 15;75(4):1018-24 [7842403.001]
  • [Cites] Ann Intern Med. 1977 Sep;87(3):293-8 [71004.001]
  • [Cites] J Urol. 1986 Dec;136(6):1221-3 [3022018.001]
  • (PMID = 11989561.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; PVB protocol
  •  go-up   go-down


5. Oottamasathien S, Thomas JC, Adams MC, DeMarco RT, Brock JW 3rd, Pope JC 4th: Testicular tumours in children: a single-institutional experience. BJU Int; 2007 May;99(5):1123-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular tumours in children: a single-institutional experience.
  • OBJECTIVE: To report our experience of testicular and paratesticular tumours in children, as such tumours are rare, and historically yolk sac tumour has been described as the most common lesion in children, but recent reports suggest that benign testicular lesions might be more common.
  • PATIENTS AND METHODS: We reviewed retrospectively the records of children treated for testicular tumours from 1998 to 2005.
  • The patients' age, clinical presentation, diagnostic procedures, treatment methods, histopathological findings, and outcome were recorded.
  • Pathological analysis revealed teratoma in four patients, yolk sac tumour in two, epidermoid cysts in two, extrarenal nephroblastomatosis in one, and paratesticular rhabdomyosarcomas in two.
  • The most common clinical presentation was a painless testicular mass.
  • Depending on the clinical presentation and pathology, scrotal ultrasonography, tumour markers (alpha-fetoprotein and beta-human chorionic gonadotrophin), and/or staging computed tomography (CT) were obtained in eight patients.
  • Chemotherapy was administered to both patients with rhabdomyosarcoma.
  • CONCLUSION: Although there were few patients, most of the lesions were benign tumours, with the most common histological subtype being teratoma.
  • As both malignant and paratesticular lesions occurred at a significant frequency, we would continue to advocate an initial radical inguinal approach at which time testis-sparing could be considered if the preoperative evaluation was favourable, and frozen-section analysis at the time of surgery confirms a benign lesion.
  • [MeSH-major] Orchiectomy / methods. Testicular Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Chorionic Gonadotropin, beta Subunit, Human / metabolism. Humans. Infant. Infant, Newborn. Male. Retrospective Studies. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / surgery. Tomography, X-Ray Computed. Treatment Outcome. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17437431.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins
  •  go-up   go-down


6. Berney DM, Shamash J, Gaffney J, Jordan S, Oliver RT: DNA topoisomerase I and II expression in drug resistant germ cell tumours. Br J Cancer; 2002 Sep 9;87(6):624-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA topoisomerase I and II expression in drug resistant germ cell tumours.
  • A small number of testicular germ cell tumours are refractory to current chemotherapy regimens.
  • DNA topoisomerase I is the target for several new drugs and a potential candidate treatment for chemorefractory germ cell tumours.
  • DNA topoisomerase II alpha is the target for etoposide, which is currently used regularly in germ cell tumour treatment.
  • The expression of DNA topoisomerase I and II alpha were therefore assessed immunohistochemically in a range of testicular tumours, especially those with persistent malignant elements on retroperitoneal lymph node dissection.
  • Pre-chemotherapy orchidectomy specimens were matched with post-chemotherapy retroperitoneal lymph node dissections to examine changes in expression.
  • There was considerable variation in the expression of topoisomerase I in different tumour types.
  • Both yolk sac tumours and teratoma, mature showed universal expression of topoisomerase I, while 38% of seminomas and 30% of embryonal carcinomas were positive.
  • There was a negative correlation between topoisomerase I and II alpha expression (P=0.004) and downregulation of topoisomerase II alpha after chemotherapy (P=0.02).
  • Topoisomerase I expression appears to increase in those cases with residual teratoma, mature, but is largely unchanged in those cases remaining as embryonal carcinoma.
  • These results suggest that topoisomerase I inhibitors may be useful in chemorefractory germ cell tumours, especially yolk sac tumours and where there are unresectable residual teratoma, mature deposits.
  • [MeSH-major] Carcinoma, Embryonal / metabolism. DNA Topoisomerases, Type I / metabolism. DNA Topoisomerases, Type II / metabolism. Drug Resistance, Neoplasm. Seminoma / metabolism. Teratoma / metabolism. Testicular Neoplasms / metabolism
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Case-Control Studies. Cisplatin / administration & dosage. Down-Regulation. Etoposide / administration & dosage. Humans. Immunoenzyme Techniques. Ki-67 Antigen / metabolism. Male. Testis / chemistry. Testis / pathology

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] APMIS. 2000 Mar;108(3):209-15 [10752690.001]
  • [Cites] Hum Pathol. 2000 Feb;31(2):214-9 [10685636.001]
  • [Cites] Hum Pathol. 2000 Jun;31(6):728-33 [10872667.001]
  • [Cites] Lab Invest. 2000 Jun;80(6):787-95 [10879730.001]
  • [Cites] J Urol. 2000 Aug;164(2):381-4 [10893590.001]
  • [Cites] Brain Tumor Pathol. 2000;17(1):7-13 [10982004.001]
  • [Cites] Br J Cancer. 2001 Feb 2;84(3):340-3 [11161398.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2647-57 [11352956.001]
  • [Cites] Histopathology. 2001 Oct;39(4):382-5 [11683938.001]
  • [Cites] Anticancer Res. 2001 Jul-Aug;21(4B):2925-32 [11712788.001]
  • [Cites] Cancer. 1981 Aug 15;48(4):904-8 [6168361.001]
  • [Cites] Br J Cancer. 1984 Nov;50(5):601-9 [6093838.001]
  • [Cites] N Engl J Med. 1987 Dec 3;317(23):1433-8 [2446132.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):6919-24 [1698546.001]
  • [Cites] Cancer Res. 1992 Feb 1;52(3):525-32 [1310066.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1294-9 [8391067.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):120-6 [7505805.001]
  • [Cites] Cancer Res. 1994 Jan 15;54(2):539-46 [8275492.001]
  • [Cites] J Urol. 1994 Oct;152(4):1144-9 [8072083.001]
  • [Cites] Int J Cancer. 1994 Dec 1;59(5):607-11 [7960233.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2129-34 [7743513.001]
  • [Cites] Br J Cancer. 1995 Dec;72(6):1454-61 [8519659.001]
  • [Cites] Anticancer Res. 1995 Sep-Oct;15(5B):2117-20 [8572612.001]
  • [Cites] J Cell Biol. 1996 Aug;134(3):757-70 [8707853.001]
  • [Cites] Annu Rev Biochem. 1996;65:635-92 [8811192.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):594-603 [9053482.001]
  • [Cites] Eur Urol. 1997;31(1):92-6 [9032542.001]
  • [Cites] Cancer Res. 1997 Apr 15;57(8):1425-8 [9108439.001]
  • [Cites] Nucleic Acids Res. 1997 Nov 1;25(21):4181-6 [9336444.001]
  • [Cites] Cancer Res. 1997 Dec 15;57(24):5475-9 [9407953.001]
  • [Cites] Mol Pathol. 1997 Oct;50(5):247-53 [9497914.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2500-4 [9667270.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):107-19 [9748525.001]
  • [Cites] Hum Pathol. 1999 Apr;30(4):384-91 [10208458.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):685-92 [10442191.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4237-41 [10485464.001]
  • [Cites] Ann Oncol. 1998 Mar;9(3):313-9 [9602266.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):257-73 [10680894.001]
  • [Cites] Hum Pathol. 2000 Jun;31(6):631-2 [10872653.001]
  • (PMID = 12237772.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 6PLQ3CP4P3 / Etoposide; EC 5.99.1.2 / DNA Topoisomerases, Type I; EC 5.99.1.3 / DNA Topoisomerases, Type II; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2364243
  •  go-up   go-down


7. Hendry WF, Norman AR, Dearnaley DP, Fisher C, Nicholls J, Huddart RA, Horwich A: Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer; 2002 Mar 15;94(6):1668-76
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses.
  • BACKGROUND: A mass may persist in the para-aortic region after patients undergo chemotherapy for metastatic, nonseminomatous germ cell tumor of the testis (NSGCT).
  • Retroperitoneal lymphadenectomy removes the mass, which may contain residual active malignancy, and allows histologic assessment of the effectiveness of the chemotherapy.
  • METHODS: After receiving chemotherapy for metastatic NSGCT, 442 men underwent lymphadenectomy for residual masses (measuring > or = 1 cm in greatest dimension) between 1976 and 1999, inclusive.
  • Three hundred thirty men underwent elective surgery within 3 months of the completion of chemotherapy, and 112 men underwent salvage surgery after receiving reinduction chemotherapy for tumor recurrence.
  • There was malignant teratoma, undifferentiated in 8.5% of patients in the elective surgery group and in 49% of patients in the salvage surgery group (P < 0.001).
  • Differentiated teratoma and necrosis/fibrosis were present in 66.0% and 25.4% of patients in the elective surgery group, respectively, and in 38.4% and 12.5% of patients in the salvage surgery group, respectively.
  • For the salvage surgery group, the completeness of surgical excision and the presence of undifferentiated teratoma were of overriding importance for overall survival.
  • Because it is not possible to predict with sufficient accuracy which patients will have favorable pathology (necrosis/fibrosis), the authors continue to recommend elective surgery for all suitable men with residual masses after they receive first-line chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Germinoma / surgery. Neoplasm Recurrence, Local. Neoplasm, Residual / surgery. Retroperitoneal Neoplasms / secondary. Testicular Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Elective Surgical Procedures. Humans. Lymph Node Excision. Male. Middle Aged. Morbidity. Prognosis. Retrospective Studies. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 11920527.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Kume H, Kakutani S, Tomita K, Kitamura T: Salvage combination chemotherapy with docetaxel, ifosfamide and cisplatin (DIP): successful treatment of a case with metastatic testicular immature teratoma. Jpn J Clin Oncol; 2008 Feb;38(2):143-5
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage combination chemotherapy with docetaxel, ifosfamide and cisplatin (DIP): successful treatment of a case with metastatic testicular immature teratoma.
  • We present a case of metastatic testicular immature teratoma that was successfully treated despite resistance to standard chemotherapy and unsuccessful salvage surgery.
  • At first, BEP (bleomycin, etoposide and cisplatin) treatment was performed but failed.
  • By the time of the referral lung and mediastinal lymph node metastasis had appeared and para-aortic lymph node metastasis had grown larger.
  • We administered the DIP (docetaxel, ifosfamide and cisplatin) regimen as a second line chemotherapy, which was effective with 82% reduction of para-aortic lymph nodes, 88% of mediastinal lymph nodes and 85% of lung metastasis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Salvage Therapy / methods. Teratoma / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Humans. Ifosfamide / administration & dosage. Lymph Node Excision. Lymphatic Metastasis. Male. Mediastinum. Taxoids / administration & dosage. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18250203.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


9. Calaminus G, Schneider DT, Weissbach L, Schönberger S, Okpanyi V, Leuschner I, Poremba C, Göbel U: Survival after an antiangiogenetic therapy and surgery in a wide spread growing teratoma originating from a testicular mixed malignant germ cell tumor. Klin Padiatr; 2009 May-Jun;221(3):136-40
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after an antiangiogenetic therapy and surgery in a wide spread growing teratoma originating from a testicular mixed malignant germ cell tumor.
  • Growing teratoma is still an often unsolved problem especially in male with mixed malignant GCTs of the testis or the mediastinum.
  • This specific situation with progressive tumor growth and simultaneous normalization of tumor markers during or after treatment of malignant GCTs with teratomatous elements is judged as a fatal situation if this situation can not be controlled by extensive surgery, as teratoma are not sensible to chemotherapy or irradiation.
  • Here, we report the case history of a 17-year old male patient with a testicular malignant GCT and wide spread lymph node metastases, who developed a rapidly progressive growing teratoma within the lymph node metastases.
  • Within the molecular profile of the tumor we could find a cytogenetic picture typically found in malignant adult GCTs.
  • However, following an individual treatment attempt, this patient was treated with a four-agent combination of drugs with antiangiogenetic potential as well as low-dose cyclic chemotherapy.
  • We therefore would like to highlight this treatment approach in unresectable growing teratoma and would like to stimulate further research and collaboration to come to an optimized treatment suggestion for this group of poor prognostic patients.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endodermal Sinus Tumor / drug therapy. Endodermal Sinus Tumor / surgery. Lymph Node Excision. Lymphatic Metastasis. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / surgery. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / surgery. Teratoma / drug therapy. Teratoma / surgery. Testicular Neoplasms / drug therapy. Testicular Neoplasms / surgery
  • [MeSH-minor] Adolescent. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Humanized. Bevacizumab. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Follow-Up Studies. Humans. Interferon-alpha / administration & dosage. Interferon-alpha / adverse effects. Lymph Nodes / blood supply. Lymph Nodes / pathology. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Recombinant Proteins. Reoperation. Salvage Therapy. Survival Rate. Thalidomide / administration & dosage. Thalidomide / adverse effects. Tomography, X-Ray Computed. Vinblastine / administration & dosage. Vinblastine / adverse effects

  • Genetic Alliance. consumer health - Malignant germ cell tumor.
  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Klin Padiatr. 2009 May-Jun;221(3):134-5 [19437359.001]
  • (PMID = 19437360.001).
  • [ISSN] 1439-3824
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Interferon-alpha; 0 / Recombinant Proteins; 2S9ZZM9Q9V / Bevacizumab; 4Z8R6ORS6L / Thalidomide; 5V9KLZ54CY / Vinblastine; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


10. Porcaro AB, Antoniolli SZ, Martignoni G, Brunelli M, Curti P: Adult primary teratoma of the testis--report on 5 cases in clinical stage I disease. Int Urol Nephrol; 2001;33(4):657-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult primary teratoma of the testis--report on 5 cases in clinical stage I disease.
  • OBJECTIVES: Testis pure teratoma accounts for 2.7% to 3% of all germ cell tumors in adult where it behaves as a malignant neoplasm.
  • Pure teratoma of the testis presents in clinical stage I disease in 44% of the patients whose risk of having pathological stage II disease is 16.7% to 19.2%.
  • Herein we report on 5 cases of adult pure teratoma of the testis presenting itself in clinical stage I disease.
  • MATERIALS AND METHODS: From September 1976 to February 2000, 75 patients underwent orchidectomy for clinical stage I nonseminomatous germ cell cancer of the testis.
  • Testis pure teratoma was detected in 5 patients (7%).
  • Testis tumor markers were evaluated in all cases.
  • Treatment options after orchidectomy included retroperitoneal lymph node dissection (RPLND) in 4 patients and surveillance in 1.
  • Histopathology detected the following subtypes: mature teratoma in 3 cases (60%), immature teratoma in 1 (20%) and teratoma with malignant transformation in (20%).
  • CONCLUSIONS: Primary pure teratoma of the testis does not respond to chemotherapy nor does it to radiation therapy.
  • The disease treatment options after orchidectomy for patients with clinical stage I disease include RPLND or surveillance with their relative risks and benefits.
  • RPLND is the chosen treatment because it is both staging and treating.
  • A close a long term follow up is required since pure teratoma metastatic disease may clinically develop after more than 10 years.
  • [MeSH-major] Orchiectomy. Teratoma / surgery. Testicular Neoplasms / surgery

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urol Clin North Am. 1999 Aug;26(3):595-609 [10494291.001]
  • [Cites] J Urol. 1975 Oct;114(4):636-9 [1235398.001]
  • [Cites] Prog Clin Biol Res. 1990;357:267-76 [2217471.001]
  • [Cites] J Urol. 1996 Mar;155(3):939-42 [8583612.001]
  • [Cites] Acta Radiol Oncol. 1984;23(4):239-47 [6093440.001]
  • [Cites] Lancet. 1987 Aug 8;2(8554):294-8 [2886764.001]
  • [Cites] J Urol. 1986 May;135(5):1020-2 [3959229.001]
  • [Cites] Virchows Arch. 2000 Jun;436(6):608-16 [10917177.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):564-8 [1312585.001]
  • [Cites] Am J Surg Pathol. 1997 Aug;21(8):896-904 [9255252.001]
  • [Cites] Am J Surg Pathol. 1993 Nov;17(11):1075-91 [8214253.001]
  • [Cites] J Urol. 1997 Jan;157(1):160-3 [8976241.001]
  • [Cites] J Urol. 1998 Mar;159(3):859-63 [9474169.001]
  • [Cites] J Urol. 1998 Jan;159(1):133-8 [9400455.001]
  • [Cites] Cancer. 1995 May 1;75(9):2244-50 [7712432.001]
  • [Cites] Br J Urol. 1991 Feb;67(2):195-202 [2004236.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):860-3 [2990657.001]
  • [Cites] Urol Clin North Am. 1993 Feb;20(1):145-52 [8434433.001]
  • [Cites] Cancer. 1988 Sep 15;62(6):1202-6 [2842034.001]
  • [Cites] Br J Urol. 1994 Jun;73(6):701-6 [8032840.001]
  • (PMID = 12452623.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


11. Labarthe P, Khedis M, Chevreau C, Mazerolles C, Thoulouzan M, Durand X, Soulie M, Rischmann P, Plante P, Thonneau P, Houlgatte A, Huyghe E: [Management of pure teratoma of the testis in adult, results of a multicenter study over 15 years]. Prog Urol; 2008 Dec;18(13):1075-81
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of pure teratoma of the testis in adult, results of a multicenter study over 15 years].
  • [Transliterated title] Prise en charge du tératome pur testiculaire postpubertaire à propos d'une série multicentrique sur 15 ans.
  • OBJECTIVE: To analyze cases of pure teratoma of the testis (PTT) of a large population-based study, as such tumors are rare, and to make an update on the topic.
  • Among more than 1000 cases of testis cancer, we identified 20 cases of PTT (4% of the whole population).
  • For the localized PTT patients, four out of eight out of 8 were on surveillance only after the orchiectomy, and the remaining four received adjuvant chemotherapy.
  • All patients with the metastatic disease were treated by chemotherapy followed by surgical removal of residual tumor masses.
  • With a mean of 125 months follow-up, 85% of the population did not relapse after treatment.
  • CONCLUSION: We confirm that PTT is a malignant disease with a good prognosis.
  • As its management differs from the other non-seminomatous germ cell tumors, the diagnosis of PTT must be with certainty.
  • [MeSH-major] Teratoma / therapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Humans. Male. Middle Aged. Prospective Studies. Time Factors. Young Adult

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19041814.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] France
  •  go-up   go-down


12. Terenziani M, D'Angelo P, Bisogno G, Boldrini R, Cecchetto G, Collini P, Conte M, De Laurentis T, Ilari I, Indolfi P, Inserra A, Piva L, Siracusa F, Spreafico F, Tamaro P, Lo Curto M: Teratoma with a malignant somatic component in pediatric patients: the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience. Pediatr Blood Cancer; 2010 Apr;54(4):532-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Teratoma with a malignant somatic component in pediatric patients: the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience.
  • BACKGROUND: Teratoma with a malignant somatic component (TMSC) is rare but described in adults, whereas information on pediatric presentation is sparse.
  • PROCEDURE: The Associazione Italiana Ematologia Oncologia Pediatrica identified 14 cases of TMSC.
  • RESULTS: The series (9 female, 5 male) showed the following disease: testis (2), sacrococcygeal (3), ovary (3), retroperitoneum (3), mediastinum (2), and foot soft tissue (1).
  • Distribution of the somatic component was: carcinoma (4), pancreatic neuroendocrine tumor (1), neuroblastoma (3), rhabdomyosarcoma (3), rhabdomyosarcoma plus liposarcoma, chondrosarcoma, neurogenic sarcoma (1), chondrosarcoma plus neuroectodermal sarcoma (1), malignant peripheral nerve sheath tumor (1).
  • Chemotherapy optimized for histology should include reagents directed to the somatic malignancy, if chemosensitive.
  • Malignant GCT warrants GCT-directed chemotherapy.
  • [MeSH-major] Teratoma / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Italy. Male. Neoplasm Staging. Prognosis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20049928.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Maldonado-Valadez R, Schilling D, Anastasiadis AG, Sturm W, Stenzl A, Corvin S: Post-chemotherapy laparoscopic retroperitoneal lymph-node dissection in testis cancer patients. J Endourol; 2007 Dec;21(12):1501-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-chemotherapy laparoscopic retroperitoneal lymph-node dissection in testis cancer patients.
  • BACKGROUND AND PURPOSE: Retroperitoneal lymph node dissection (RPLND) is still the most sensitive and specific method for the detection of malignant tumor and mature teratoma in stage II nonseminomatous testicular carcinoma after chemotherapy.
  • In this study, we describe our experiences with laparoscopic RPLND for stage II testicular carcinoma after chemotherapy.
  • METHODS: Sixteen patients underwent 17 laparoscopic RPLND after chemotherapy for clinical stage IIA-III nonseminomatous testicular cancer.
  • Patients with post-chemotherapy residual masses >1 cm and normalization of tumor markers were considered for the procedure.
  • Operative time ranged from 125 to 370 minutes (mean 240 +/- 56 min).
  • No transfusions were required, and no intra- or postoperative complications occurred because of the procedure.
  • A bleomycin-induced interstitial pneumonia developed in one patient.
  • CONCLUSION: Laparoscopic RPLND after chemotherapy is a feasible and oncologically safe procedure.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18186691.001).
  • [ISSN] 0892-7790
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


14. Harland SJ, Welch R, Huddart R, Stenning S, Pollock P, Gabe R: On the necessity for postchemotherapy surgery for residual abdominal masses in metastatic nonseminomatous germ cell tumors (NSGCT) of testis. J Clin Oncol; 2009 May 20;27(15_suppl):5088

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] On the necessity for postchemotherapy surgery for residual abdominal masses in metastatic nonseminomatous germ cell tumors (NSGCT) of testis.
  • : 5088 Background: Residual abdominal masses after chemotherapy for metastatic NSGCT of testis may contain viable tumor-derived tissue which can be a nidus for relapse of disease, particularly when the tissue is frankly malignant.
  • This justifies routine retroperitoneal lymph node dissection (RPLND) for large masses where malignant tissue is found at an appreciable rate.
  • Yet RPLND is often carried out for smaller, or even absent, residual masses and differentiated teratoma (TD) is commonly found.
  • METHODS: 51 patients were identified from the MRC patients entered into the TE20 trial of 3 vs 4 cycles of BEP for good prognosis metastatic NSGCT who fell into the following category: metastatic NSGCT, residual abdominal mass only, unresected post-chemotherapy, response evaluation: CR or PR marker -ve.
  • Follow-up from the end of chemotherapy was >3years in all but two cases and the median was 5 years.
  • One patient suffered a relapse one year after the surgery which took place 4.5 years after chemotherapy.
  • Of the 41 patients who did not undergo surgery, 37 were considered on subsequent CTs to have normal appearances without further treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964289.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Brames M, Ehrlich Y, Einhorn L: Malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): Outcome analysis with PNET based chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e16121

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): Outcome analysis with PNET based chemotherapy.
  • : e16121 Background: Metastatic testis cancer is uniquely chemosensitive and highly curable.
  • Residual teratoma can be surgically resected.
  • However, testicular teratoma can differentiate along endodermal, ectodermal, or mesodermal elements (malignant transformation of teratoma), with capacity to metastasize and not be amenable to surgical resection.
  • We report results of malignant transformation of teratoma to metastatic PNET treated with PNET based chemotherapy.
  • METHODS: Retrospective review of 42 patients with PNET in testis or at metastatic sites seen at Indiana University from 1999-2007.
  • RESULTS: 9 of 10 patients had at least 1 prior platinum based combination chemotherapy regimen for their germ cell tumor.
  • Tumor markers (human chorionic gonadotropin and alphafetoprotein) were normal at start of chemotherapy for biopsy proven PNET.
  • Two of 10 are currently disease-free for 16 and 33 months from initiation of PNET specific chemotherapy and 3 other patients are alive with disease at 73, 34, and 30 months.
  • CONCLUSIONS: PNET specific chemotherapy has a high objective response rate for malignant transformation of teratoma to PNET, with some patients capable of long-term survival with chemotherapy followed by surgical resection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963389.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Foster R, Ehrlich Y, Ulbright TM, Cheng L, Bihrle R, Beck SD, Andreoiu M, Brames MJ, Einhorn LH: Malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): Outcome analysis with retroperitoneal lymph node dissection and PNET specific chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):5081

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): Outcome analysis with retroperitoneal lymph node dissection and PNET specific chemotherapy.
  • : 5081 Background: Malignant transformation of teratoma to PNET is a rare entity.
  • Surgical resection has been the mainstay of therapy because these tumors are not curable with cisplatin based chemotherapy.
  • We report long-term survival and potential cure with retroperitoneal lymph node dissection (RPLND) and PNET specific chemotherapy.
  • METHODS: Retrospective review of 75 patients (pts) with PNET in the testis or at distant metastasis treated from Jan 1988 to Dec 2007.
  • 74 had RPLND as part of initial treatment or at relapse.
  • PNET specific chemotherapy consisted of cyclophosphamide, doxorubicin, vincristine alternating with ifosfamide and etoposide.
  • 9 elected surveillance or adjuvant chemotherapy.
  • 10 of these were treated with PNET specific chemotherapy for unresectable disease.
  • 2 additional pts were treated with PNET specific chemotherapy as adjuvant to RPLND.
  • CONCLUSIONS: Malignant transformation of teratoma to PNET carries an adverse prognosis.
  • RPLND is an integral part of the therapeutic strategy.
  • PNET specific chemotherapy, adjuvant to RPLND or for treatment of unresectable disease followed by surgery, may result in long-term survival and potential cure.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964284.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Ross JH, Rybicki L, Kay R: Clinical behavior and a contemporary management algorithm for prepubertal testis tumors: a summary of the Prepubertal Testis Tumor Registry. J Urol; 2002 Oct;168(4 Pt 2):1675-8; discussion 1678-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical behavior and a contemporary management algorithm for prepubertal testis tumors: a summary of the Prepubertal Testis Tumor Registry.
  • PURPOSE: The Prepubertal Testis Tumor Registry was established by the Urologic Section of the American Academy of Pediatrics in 1980 to record data on a large number of prepubertal testis tumors regarding presentation, treatment and outcome to define appropriate management better.
  • MATERIALS AND METHODS: Relevant data in the prepubertal testis tumor registry were tabulated and analyzed.
  • RESULTS: There were 395 prepubertal patients who had a primary testis tumor.
  • A significant proportion of tumors were benign regardless of patient age. alpha-Fetoprotein levels for patients with benign and malignant tumors overlapped in children younger than 6 months.
  • There were no metastases or deaths among the patients with teratoma.
  • Of all patients with stromal tumors metastases developed in only 1.
  • CONCLUSIONS: We recommend initial excisional biopsy for all amenable prepubertal testis tumors, except those with an alpha-fetoprotein level that is clearly increased for patient age.
  • Patients with stage I yolk sac tumor should be monitored closely, and those with recurrent or metastatic yolk sac tumor should be treated with chemotherapy.
  • Retroperitoneal lymph node dissection is reserved for patients with recurrent retroperitoneal masses following chemotherapy.
  • Aggressive treatment of metastatic Sertoli cell or undifferentiated stromal tumors is warranted.
  • [MeSH-major] Registries / statistics & numerical data. Testicular Neoplasms / congenital
  • [MeSH-minor] Algorithms. Child. Child, Preschool. Combined Modality Therapy. Endodermal Sinus Tumor / congenital. Endodermal Sinus Tumor / mortality. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / therapy. Humans. Infant. Male. Neoplasm Staging. Prognosis. Sertoli Cell Tumor / congenital. Sertoli Cell Tumor / mortality. Sertoli Cell Tumor / pathology. Sertoli Cell Tumor / therapy. Sex Cord-Gonadal Stromal Tumors / congenital. Sex Cord-Gonadal Stromal Tumors / mortality. Sex Cord-Gonadal Stromal Tumors / pathology. Sex Cord-Gonadal Stromal Tumors / therapy. Survival Rate. United States. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12352332.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


18. Baretti R, Schaumann B, Meyer R, Alfaouri D, Hetzer R: [Metastasizing malignant germ cell tumor of the testis with infiltration of the thoracic aorta--a case for metastasis surgery]. Dtsch Med Wochenschr; 2000 Sep 29;125(39):1164-6
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastasizing malignant germ cell tumor of the testis with infiltration of the thoracic aorta--a case for metastasis surgery].
  • [Transliterated title] Metastasierender maligner Keimzelltumor des Hodens mit Infiltration der Aorta thoracica--Kasuistik zur Metastasenchirurgie.
  • HISTORY AND FINDINGS: A 33-year-old man was admitted 7 years after a testicular teratomatous carcinoma had first been diagnosed, treated by a right orchiectomy and two-stage radical retroperitoneal lymphadenectomy.
  • Five years later the first mediastinal metastases were treated with high-dosage chemotherapy and autologous germ-cell transplantation, and remaining paraaortic--mediastinal tumour tissue was resected.
  • A curing treatment seemed impossible, because the aortic wall had been invaded.
  • TREATMENT AND COURSE: Five months after re-thoracotomy the metastasis and the invaded aortic segment were resected, the latter replaced by a vascular prosthesis.
  • Histology indicated metastasis of a malignant teratoma of intermediate type.
  • CONCLUSION: Combined orchidectomy, lymphadenectomy, high-dosage chemotherapy with cisplatin and autologous germ-cell transplantation at present constitute the standard treatment of malignant testicular germ-cell tumour.
  • In case of metastatic infiltration of vital structures, such as the aortic wall, special operative procedures can prolong the period of remission when the success of a standard treatment seems limited.
  • [MeSH-major] Aorta, Thoracic / surgery. Teratocarcinoma / secondary. Teratocarcinoma / surgery. Testicular Neoplasms / pathology. Vascular Neoplasms / secondary. Vascular Neoplasms / surgery
  • [MeSH-minor] Adult. Aortic Diseases / radiography. Aortic Diseases / surgery. Blood Vessel Prosthesis. Chemotherapy, Adjuvant. Humans. Lymph Node Excision. Male. Mediastinal Neoplasms / secondary. Mediastinal Neoplasms / surgery. Orchiectomy. Retroperitoneal Space. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant germ cell tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11075244.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] GERMANY
  •  go-up   go-down


19. Yang WP, Zou Y, Huang CS, Zhang SZ, Xiao Q, Dai KL, Zhong HS, Xiong XJ: [Clinicopathologic and prognostic study of pediatric immature teratoma]. Zhonghua Bing Li Xue Za Zhi; 2007 Oct;36(10):666-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic and prognostic study of pediatric immature teratoma].
  • OBJECTIVE: To study the clinicopathologic features and biologic behavior of pediatric immature teratoma.
  • METHODS: The clinical data, pathologic features, immunohistochemical findings (for cyclin D1, P27 and Ki-67) and follow-up information of 39 cases of pediatric immature teratoma were analyzed.
  • RESULTS: Amongst the 39 cases studied, 12 arose in the sacrococcygeal region, 12 in testis, 5 in retroperitoneum, 4 in ovary, 4 in abdomen and 2 in mediastinum.
  • Immature neuroepithelial features used in histologic grading included the presence of primitive neural tubules, immature rosettes, undifferentiated neuroblastoma cells and primitive neuroectodermal structures.
  • The prognosis of immature teratoma in children is different from that in adults.
  • Sacrococcygeal immature teratoma occurring in patients younger than 1 year old and with low histologic grade do not require postoperative chemotherapy if the tumor is completely excised.
  • Similarly, for testicular immature teratoma occurring in patients below 1 year of age, regardless of tumor grading, need no adjunctive therapy.
  • On the other hand, ovarian immature teratoma with high histologic grade requires postoperative chemotherapy, regardless of age of the patients.
  • The presence of microscopic foci of yolk sac tumor is a useful predictor of recurrence in pediatric immature teratoma.
  • [MeSH-major] Ovarian Neoplasms / pathology. Retroperitoneal Neoplasms / pathology. Teratoma / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Cyclin D1 / metabolism. Endodermal Sinus Tumor / drug therapy. Endodermal Sinus Tumor / metabolism. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / surgery. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Ki-67 Antigen / metabolism. Male. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / metabolism. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / surgery. Neoplasm Recurrence, Local. Neoplasm Staging. Proliferating Cell Nuclear Antigen / metabolism. Sacrococcygeal Region. Survival Rate. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18194599.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / alpha-Fetoproteins; 0 / p27 antigen; 136601-57-5 / Cyclin D1
  •  go-up   go-down


20. Athanasiou A, Vanel D, El Mesbahi O, Theodore C, Fizazi K: Non-germ cell tumours arising in germ cell tumours (teratoma with malignant transformation) in men: CT and MR findings. Eur J Radiol; 2009 Feb;69(2):230-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-germ cell tumours arising in germ cell tumours (teratoma with malignant transformation) in men: CT and MR findings.
  • PURPOSE: To describe the imaging findings of germ cell tumours (GCT) containing non-germ cell malignant components (also designated teratoma with malignant transformation or TMT).
  • All patients had computed tomography (CT) and/or magnetic resonance (MR) studies before and after initial surgery and chemotherapy, as well as during follow-up.
  • Imaging findings were correlated with the response to treatment and with overall survival.
  • Other histological types of malignant transformation included adenocarcinoma (n=3) and bronchoalveolar carcinoma (n=1).
  • Overall, 9 patients relapsed at a median time of 84 months (range 60-168).
  • RESULTS: Non-GCT malignant transformation was identified in the retroperitoneum (5), testis (3), mediastinum (3), peritoneum (2) and lungs (1).
  • The CT and MR imaging findings before treatment and after relapse were evaluated with emphasis on imaging features that could possibly imply the presence of malignant transformation (heterogeneously enhancing soft-tissue masses, ossified masses with calcified lymph nodes, diffuse epiploic thickening associated with ascites and peritoneal nodules, pulmonary alveolar infiltration with septal thickening).
  • Imaging can be useful as CT and MR findings may suggest this entity and lead to an early biopsy and appropriate treatment.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Magnetic Resonance Imaging. Teratoma / diagnosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19056194.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


21. Mann JR, Gray ES, Thornton C, Raafat F, Robinson K, Collins GS, Gornall P, Huddart SN, Hale JP, Oakhill A, UK Children's Cancer Study Group Experience: Mature and immature extracranial teratomas in children: the UK Children's Cancer Study Group Experience. J Clin Oncol; 2008 Jul 20;26(21):3590-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature and immature extracranial teratomas in children: the UK Children's Cancer Study Group Experience.
  • PURPOSE: The purpose of this article is to describe the features, treatment, and risk factors for relapse of children with mature teratoma (MT) and immature teratoma (IT) to assist future treatment plans.
  • PATIENTS AND METHODS: Patients were younger than 16 years of age and referred to the UK Children's Cancer Study Group centers with biopsy-proven extracranial MT and IT and no prior chemotherapy.
  • Complete excision, with the coccyx in sacrococcygeal patients, and follow-up, including serum alpha-fetoprotein monitoring for early detection of malignant yolk sac tumor (YST) recurrence, were recommended.
  • Pathology was reviewed and treatments, outcome, and prognostic features assessed.
  • Tumor sites were: testis (n = 53), ovary (n = 130), sacrococcygeal region (n = 98), thorax (n = 23), and other (n = 47).
  • CONCLUSION: Treatment remains primarily surgical, with JEB chemotherapy for YST relapse.
  • Adjuvant chemotherapy after surgery for sacrococcygeal patients is not advocated.
  • [MeSH-major] Neoplasm Recurrence, Local / epidemiology. Teratoma / pathology. Teratoma / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Disease-Free Survival. Female. Great Britain. Humans. Infant. Male. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18541896.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


22. Game X, Houlgatte A, Fournier R, Duhamel P, Baranger B, Khoury S: [Dedifferentiation of mature teratomas secondary to testicular cancer: report of 2 cases]. Prog Urol; 2001 Feb;11(1):73-6; discussion 76-7
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Dedifferentiation of mature teratomas secondary to testicular cancer: report of 2 cases].
  • [Transliterated title] Dédifférenciation des tératomes matures secondaires à un cancer du testicule: à propos de deux cas.
  • The authors report two cases of adenocarcinomatous dedifferentiation of a recurrent mature teratoma arising 3 and 20 years after the initial resection.
  • This is a rare event, occurring after macroscopically or microscopically incomplete resection of a mature teratoma.
  • However, PET scan suggests the diagnosis of malignant teratoma in the presence of increased uptake by the lesion.
  • Treatment consists of complete resection of the tumour mass.
  • The possibility of long-term malignant dedifferentiation of a teratoma therefore requires prolonged and regular life-long surveillance of patients presenting a mature teratoma after chemotherapy for non-seminomatous germ cell tumour of the testis.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Transformation, Neoplastic / pathology. Neoplasms, Second Primary / pathology. Retroperitoneal Neoplasms / pathology. Teratoma / pathology. Testicular Neoplasms / surgery

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11296651.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


23. Allan RW, Algood CB, Shih IeM: Metastatic epithelioid trophoblastic tumor in a male patient with mixed germ-cell tumor of the testis. Am J Surg Pathol; 2009 Dec;33(12):1902-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic epithelioid trophoblastic tumor in a male patient with mixed germ-cell tumor of the testis.
  • This report describes a rare case of a concurrent epithelioid trophoblastic tumor (ETT) and a teratoma in a para-aortic lymph node from a 39-year-old male patient with the initial diagnosis of testicular malignant mixed germ-cell tumor.
  • The metastatic lesion was excised 2 years after orchiectomy and chemotherapy.
  • Microscopically, the metastatic lesion contained a teratoma component and dispersed small nests of cohesive chorionic-type intermediate trophoblastic cells, closely resembling gestational ETT in female patients.
  • The diagnosis of ETT in this case was confirmed by stepwise immunohistochemistry.
  • Demonstration of ETT as one of the histologic manifestations of recurrent testicular germ-cell tumors should encourage pathologists to recognize this unique feature in assessing posttreatment mixed germ-cell neoplasm.
  • [MeSH-major] Carcinoma, Embryonal / secondary. Choriocarcinoma, Non-gestational / secondary. Epithelioid Cells / pathology. Teratoma / secondary. Testicular Neoplasms / pathology. Trophoblastic Neoplasms / secondary
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Humans. Immunohistochemistry. Lymph Node Excision. Lymphatic Metastasis. Male. Orchiectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898219.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Barton SJ, Ashdown DA, Ganta S, Wallace D: An unusual presentation of metastatic testicular tumour. J R Army Med Corps; 2005 Mar;151(1):30-3
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual presentation of metastatic testicular tumour.
  • We report a unique case of metastatic malignant teratoma from an undescended testis which presented with acute pulmonary embolism.
  • After chemotherapy, the undescended right testicle was resected along with a cord of non- obstructing inferior venal caval tumour which extended into the right atrium with tumour floating free within the atrium at the end of the cord of tumour.
  • The presentation, diagnosis and treatment of testicular tumours is described and the literature pertaining to testicular tumours in military personnel reviewed.
  • [MeSH-major] Carcinoma, Embryonal / diagnosis. Pulmonary Embolism / diagnosis. Pulmonary Embolism / etiology. Teratoma / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Male. Military Personnel. Neoplastic Cells, Circulating. Vascular Neoplasms / diagnosis. Vascular Neoplasms / secondary. Vascular Neoplasms / surgery. Vena Cava, Inferior / pathology. Venous Thrombosis / diagnosis. Venous Thrombosis / surgery

  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15912681.001).
  • [ISSN] 0035-8665
  • [Journal-full-title] Journal of the Royal Army Medical Corps
  • [ISO-abbreviation] J R Army Med Corps
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


25. Tröbs RB, Krauss M, Geyer C, Tannapfel A, Körholz D, Hirsch W: Surgery in infants and children with testicular and paratesticular tumours: a single centre experience over a 25-year-period. Klin Padiatr; 2007 May-Jun;219(3):146-51
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery in infants and children with testicular and paratesticular tumours: a single centre experience over a 25-year-period.
  • Testicular and even more paratesticular tumours in children are rare.
  • The aim of the study is to characterise the spectrum of these lesions with focus on the feasibility and effectiveness of testis sparing surgery.
  • Generally a high rate of malignant or potentially malignant tumours was observed.
  • The spectrum of testicular tumours comprised 13 germ cell tumours (6 yolk sac tumours, 6 teratomas, 1 embryonal carcinoma) and 4 sex cord stromal tumours (2 Leydig's cell, Sertoli's cell, granulosa cell).
  • Further on, we observed 3 boys with paratesticular rhabdomyosarcoma (RMS), and three with testicular and paratesticular metastases (Wilms' tumour, neuroblastoma, leukaemia).
  • Dependent on tumour histology, stage and the recommended treatment schedule postoperative chemotherapy was added.
  • Testis sparing surgery was performed in 3 boys with primary testicular tumours (2 Leydig's cell, mature cystic teratoma).
  • During a median follow up of 5 years all patients with primary testicular tumours survived event free.
  • Meta-analysis of the recent literature revealed that testis sparing surgery is feasible and save in prepubertal boys after exclusion of a malignant tumour.
  • If a testis sparing approach is planned, the following criteria are essential: 1.
  • 3. The presence of sufficient healthy testicular parenchyma.
  • However, the high rate of malignant or potentially malignant tumours suggests that high inguinal orchidectomy should remain the surgical standard of therapy.
  • [MeSH-major] Granulosa Cell Tumor / surgery. Leydig Cell Tumor / surgery. Neoplasms, Germ Cell and Embryonal / surgery. Sertoli Cell Tumor / surgery. Testicular Neoplasms / surgery
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Child. Child, Preschool. Chorionic Gonadotropin, beta Subunit, Human / blood. Combined Modality Therapy. Diagnostic Imaging. Feasibility Studies. Follow-Up Studies. Humans. Infant. Male. Neoplasm Staging. Orchiectomy / methods. Retrospective Studies. alpha-Fetoproteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525908.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins
  •  go-up   go-down


26. Göbel U, Schneider DT, Calaminus G, Haas RJ, Schmidt P, Harms D: Germ-cell tumors in childhood and adolescence. GPOH MAKEI and the MAHO study groups. Ann Oncol; 2000 Mar;11(3):263-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In mature and immature teratoma the treatment is surgical.
  • The risk of recurrence can be estimated from the parameters primary site (with the coccygeal tumors being most at risk), histological grade of immaturity and completeness of the primary resection including the adjacent organ of origin (coccyx, ovary, testis etc.).
  • Malignant germ-cell tumors (GCT) account for 2.9% of all malignant tumors of children younger than 15 years of age.
  • In patients with extensive tumor growth, metastatic disease or secreting intracranial tumors a delayed tumor resection after preoperative chemotherapy is preferable.
  • In these patients malignant non-seminomatous GCT may be diagnosed clinically due to the increased serum or cerebrospinal fluid levels of the tumor markers AFP and/or beta-HCG.
  • Current risk adapted treatment protocols containing cisplatinum allow long-term remissions in about 80% including patients with bulky or metastatic tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10811491.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor
  • [Number-of-references] 44
  •  go-up   go-down


27. Lo Curto M, D'Angelo P, Cecchetto G, Klersy C, Dall'Igna P, Federico A, Siracusa F, Alaggio R, Bernini G, Conte M, De Laurentis T, Di Cataldo A, Inserra A, Santoro N, Tamaro P, Indolfi P: Mature and immature teratomas: results of the first paediatric Italian study. Pediatr Surg Int; 2007 Apr;23(4):315-22
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature and immature teratomas: results of the first paediatric Italian study.
  • Teratoma is the most common germ cell tumour in childhood; mature (MT) and immature teratomas (IT) are benign tumours, but if they recur, they can be in some cases malignant.
  • Clinical data, treatment and results were all analysed.
  • Chemotherapy (CT) with Vinblastine, D: -actinomycin and cyclophosphamide was indicated for extra-testicular IT grade 2 or 3.
  • MT was diagnosed in 127 patients (93 F and 34 M, age 1-192 months, median 24): 58 patients had gonadic tumour (23 testicular, 35 ovaric), 69 extragonadic (45 sacrococcygeal, 11 mediastinic, 7 retroperitoneal, 6 in other sites).
  • The T grading was 1 in 14 cases, 2 in 26, 3 in 16; 28 had gonadic T (17 ovary, 11 testis), 28 extragonadic (sacrococcygeal 19, mediastinic 3, retroperitoneal 2, other sites 4).
  • CT was administered in eight patients; 15/182 patients relapsed (1 in a metastatic site) and in 5/15 the relapse showed malignant histology.
  • Seven MT (5.5%) relapsed (five sacrococcygeal, one retroperitoneal, one mediastinic): surgery at diagnosis had been complete in five and with residual in two; the relapse was malignant in two patients with sacrococcygeal (sc) tumours, who had a complete resection and a partial resection respectively.
  • A malignant recurrence occurred in two patients with sc tumours (after partial resection in one and after biopsy + CT in one) and in one patient with ovarian IT after a partial resection.
  • All the patients underwent surgical excision of the recurred mass; CT according to Protocol for Malignant GCT was administered to those who had malignant recurrence; 122/126 patients with MT and 53/56 with IT are alive without disease with a follow up of 8-144 months (median 56).
  • Two patients with malignant relapse (one with sc MT, one with sc IT) died because of the progression of the disease.
  • The number of patients treated with CT is not sufficient to evaluate the efficacy of CT in avoiding malignant relapse.
  • [MeSH-major] Ovarian Neoplasms / epidemiology. Teratoma / epidemiology. Testicular Neoplasms / epidemiology
  • [MeSH-minor] Age Distribution. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Incidence. Infant. Infant, Newborn. Italy / epidemiology. Male. Neoplasm Staging. Prospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Klin Padiatr. 1997 Jul-Aug;209(4):228-34 [9293455.001]
  • [Cites] J Pediatr Surg. 2001 Jan;36(1):12-7 [11150431.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2137-43 [10561269.001]
  • [Cites] Med Pediatr Oncol. 2003 Nov;41(5):417-25 [14515380.001]
  • [Cites] J Pediatr Surg. 1992 Aug;27(8):1075-8; discussion 1078-9 [1403540.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):620-4 [9053485.001]
  • [Cites] J Pediatr Surg. 1987 Mar;22(3):274-7 [3559872.001]
  • [Cites] Med Pediatr Oncol. 1998 Jul;31(1):8-15 [9607423.001]
  • [Cites] Ann Surg. 1965 Dec;162(6):1091-5, 1100 [5845591.001]
  • [Cites] Crit Rev Oncol Hematol. 1990;10(2):99-110 [2163259.001]
  • [Cites] J Pediatr Surg. 1998 Feb;33(2):171-6 [9498381.001]
  • [Cites] Cancer. 1989 May 1;63(9):1657-67 [2467734.001]
  • [Cites] Pediatr Blood Cancer. 2004 Feb;42(2):169-75 [14752882.001]
  • [Cites] Crit Rev Oncol Hematol. 1990;10(2):89-98 [1694438.001]
  • [Cites] Med Pediatr Oncol. 1993;21(6):395-401 [8390599.001]
  • [Cites] Am J Obstet Gynecol. 1999 Aug;181(2):353-8 [10454682.001]
  • [Cites] J Pediatr Surg. 1974 Jun;9(3):389-98 [4843993.001]
  • [Cites] Cancer. 1976 May;37(5):2359-72 [1260722.001]
  • [Cites] AJR Am J Roentgenol. 1981 Aug;137(2):395-8 [6789651.001]
  • (PMID = 17333214.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


28. Mikuz G: [WHO classification of testicular tumors]. Verh Dtsch Ges Pathol; 2002;86:67-75
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [WHO classification of testicular tumors].
  • [Transliterated title] WHO-Klassifikation der Hodentumoren.
  • Twenty years after the first edition (1977), the WHO has presented the updated version of the "Histological typing of testis tumours".
  • The most important is obviously the precursor lesion of germ cell tumors, which has been called "intratubular malignant germ cells".
  • Such atypical cells appear in the tubules adjacent to the germ cell tumors, in some few cases (6%) also in the contra lateral healthy gonad and rarely in infertile men (1%).
  • The precursor lesion can progress to franc germ cell tumor starting probably with seminoma, which still maintain the capability of differentiation (pluripotente cells) in all other types of non-seminomatous germ cell tumors.
  • Unfortunately, however, the old term "teratoma with malignant transformation" was changed to "teratoma with malignant areas" in the 1998 classification.
  • This is a harmless name for an extremely dangerous tumor in which one tissue overgrows the other and gives rise to somatic type sarcomas or carcinomas.
  • Such tumors do not respond like germ cell tumors to the usual chemotherapy.
  • Treatment should be tailored according to that used in standard management of the respective sarcoma or carcinoma.
  • In the comments it is mentioned that the testis carcinoid could be a part of teratoma, but the diagnosis is listed in the group of "miscellaneous" tumors together with tumors of ovarian epithelial type.
  • This is a very questionable decision because the normal testis does not contain neuroendocrine cells from which carcinoids would have to be able to develop.
  • The patients have cardiac myxomas, spotty skin pigmentation, hormone active nodular hyperplasia of the adrenals and soft tissue myxomas.
  • For the therapy of germ cell tumor an assessment of risk factors found by the pathologists is extremely important.
  • In the absence of such predictors a surveillance policy allows some patients to forgo chemotherapy.
  • [MeSH-major] Testicular Neoplasms / classification

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12647353.001).
  • [ISSN] 0070-4113
  • [Journal-full-title] Verhandlungen der Deutschen Gesellschaft für Pathologie
  • [ISO-abbreviation] Verh Dtsch Ges Pathol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 48
  •  go-up   go-down


29. Opot EN, Magoha GA: Testicular cancer at Kenyatta National Hospital, Nairobi. East Afr Med J; 2000 Feb;77(2):80-5
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular cancer at Kenyatta National Hospital, Nairobi.
  • OBJECTIVE: To determine the prevalence, clinical characteristics, management methods and prognosis of testicular cancer at Kenyatta National Hospital.
  • DESIGN: Retrospective case study of testicular cancer patients over a fifteen year period.
  • PARTICIPANTS: All histologically confirmed testicular cancer patients recorded at the Histopathology Department of Kenyatta National Hospital between 1983 and 1997.
  • Thirty one patients (79.49%) presented with painless testicular swellings, eleven (28.08%) with pain, nine (23.08%) with scrotal heaviness, six (15.38%) with abdominal swellings and one (2.56%) each with gynaecomastia and eye swelling.
  • On examination 32 patients (82.05%) had testicular masses, ten (25.64%) had abdominal masses, seven (17.91%) had supraclavicular and cervical lymphadenopathy, and one each (2.56%) had gynaecomastia and eye mass respectively.
  • More than eighty nine per cent had germ cell cancers with seminoma accounting for 67.35%, teratoma 12.24%, embroyonal carcinoma 8.16%, rhabdomyosarcoma 6.12% and malignant germ cell tumour, orchioblastoma and dysgerminoma each accounted for 2.04%.
  • Three patients (7.7%) had orchidectomy and radiotherapy and chemotherapy, sixteen (41.03%) had orchidectomy and radiotherapy, six (15.38%) had orchidectomy and chemotherapy, ten (25.64%) had radiotherapy and chemotherapy, three (7.7%) and two (5.13%) had only chemotherapy and radiotherapy respectively.
  • No cisplastin based chemotherapy regime was used.
  • Cisplastin based chemotherapy with up to 90% cure rates should be included as a component of testicular cancer management at Kenyatta National Hospital.
  • This retrospective study was undertaken to determine the prevalence, clinical characteristics, management methods and prognosis of testicular cancer at Kenyatta National Hospital, Nairobi.
  • All histologically confirmed testicular cancer patients recorded at the Histopathology Department between 1993 and 1997 were analyzed.
  • The clinical symptoms presented were painless testicular swelling (n = 31, 79.49%), testicular pain (n = 11, 28.08%), scrotal heaviness (n = 9, 23.08%), abdominal swelling (n = 6, 15.38%), gynecomastia (n = 1, 2.56%), and eye swelling (n = 1, 2.56%).
  • On examination, 32 patients (82.05%) had testicular masses, 10 (25.64%) had abdominal masses, 7 (17.91%) had supraclavicular and cervical lymphadenopathy, 1 had gynecomastia, and 1 had an orbital mass.
  • More than 89% of patients had germ cell cancers with seminoma accounting for 67.35%, teratoma for 12.24%, embryonal carcinoma for 8.16%, rhabdomyosarcoma for 6.12%, and malignant germ cell tumor, orchioblastoma, and dysgerminoma each accounting for 2.04%.
  • The various methods of treatment include orchidectomy and radiotherapy and chemotherapy in 3 patients (7.7%), orchidectomy and radiotherapy in 16 patients (41.03%), orchidectomy and chemotherapy in 6 patients (15.38%), and radiotherapy and chemotherapy in 10 patients (25.64%).
  • No cisplatin-based chemotherapy was used.
  • Hence, cisplatin-based chemotherapy with up to 90% cure rates should be included in the testicular cancer management in this hospital.
  • [MeSH-major] Testicular Neoplasms / diagnosis. Testicular Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Child. Child, Preschool. Combined Modality Therapy. Hospitals, Teaching. Humans. Incidence. Kenya / epidemiology. Male. Middle Aged. Orchiectomy. Prognosis. Referral and Consultation. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10774080.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] KENYA
  • [Other-IDs] PIP/ 149564; POP/ 00296083
  • [Keywords] PIP ; Cancer (major topic) / Clinical Research (major topic) / Prevalence (major topic) / Research Report (major topic) / Retrospective Studies (major topic) / Signs And Symptoms (major topic) / Testis (major topic) / Treatment (major topic) / Africa / Africa South Of The Sahara / Biology / Developing Countries / Diseases / Eastern Africa / English Speaking Africa / Genitalia / Genitalia, Male / Kenya / Measurement / Neoplasms / Physiology / Research Methodology / Studies / Urogenital System
  • [General-notes] PIP/ TJ: EAST AFRICAN MEDICAL JOURNAL.
  •  go-up   go-down


30. Hughes PD: Partial orchidectomy for malignancy with consideration of carcinoma in situ. ANZ J Surg; 2006 Jan-Feb;76(1-2):92-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: This article reports partial orchidectomy for malignant tumour in a solitary testis and discusses the common occurrence of carcinoma in situ (CIS) in the non-tumour part of a testis containing malignant tumour, or in 5% of the contralateral testis when malignant tumour is found in one testis.
  • METHOD: Ultrasound of the testis gave the appearance of a 21-mm germ cell tumour in the lower pole of a solitary testis in a 20-year-old man.
  • Chest X-ray was clear, and blood testis tumour markers were negative.
  • The testis was explored through a groin incision and then the palpable tumour together with a margin of normal-looking testis was excised.
  • RESULTS: Histology showed embryonal carcinoma with no CIS in the adjacent normal testis tissue that had been excised with the tumour.
  • At 93 months postoperatively, computed tomography scans of the chest and abdomen were negative, as were blood testis tumour markers, and the patient is potent.
  • Ultrasound shows a testis of normal size and consistency.
  • CONCLUSION: Partial orchidectomy was practical in this case, but CIS is common in the non-tumour part of any testis containing germ cell tumour and should be searched for histologically.
  • Testis CIS leads to invasive carcinoma within 5 years in 50% of cases.
  • When CIS is present, local radiation therapy is recommended by Heidenreich et al.
  • Some are treating with chemotherapy CIS or germ cell primary tumours other than teratoma, in an attempt to preserve both potency and fertility.
  • [MeSH-major] Carcinoma in Situ / surgery. Orchiectomy / methods. Testicular Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16483305.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down






Advertisement